Cite
Louveau B, Resche-Rigon M, Lesimple T, et al. Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in . Clin Cancer Res. 2021;27(14):3876-3883doi: 10.1158/1078-0432.CCR-20-4050.
Louveau, B., Resche-Rigon, M., Lesimple, T., Da Meda, L., Pracht, M., Baroudjian, B., Delyon, J., Amini-Adle, M., Dutriaux, C., Reger de Moura, C., Sadoux, A., Jouenne, F., Ghrieb, Z., Vilquin, P., Bouton, D., Tibi, A., Huguet, S., Rezai, K., Battistella, M., Mourah, S., & Lebbe, C. (2021). Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in . Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3876-3883. https://doi.org/10.1158/1078-0432.CCR-20-4050
Louveau, Baptiste, et al. "Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in ." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,14 (2021): 3876-3883. doi: https://doi.org/10.1158/1078-0432.CCR-20-4050
Louveau B, Resche-Rigon M, Lesimple T, Da Meda L, Pracht M, Baroudjian B, Delyon J, Amini-Adle M, Dutriaux C, Reger de Moura C, Sadoux A, Jouenne F, Ghrieb Z, Vilquin P, Bouton D, Tibi A, Huguet S, Rezai K, Battistella M, Mourah S, Lebbe C. Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in . Clin Cancer Res. 2021 Jul 15;27(14):3876-3883. doi: 10.1158/1078-0432.CCR-20-4050. Epub 2021 May 04. PMID: 33947696.
Copy
Download .nbib